Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans
- 8 March 2012
- journal article
- research article
- Published by SAGE Publications in Vascular Medicine
- Vol. 17 (2) , 73-78
Abstract
The pathogenic mechanisms of thromboangiitis obliterans (TAO) are not entirely known and the imbalance of matrix metalloproteinases (MMPs) plays a role in vascular diseases. We evaluated the MMP-2 and MMP-9 circulating levels and their endogenous tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in TAO patients with clinical manifestations. The study included 20 TAO patients (n = 10 female, n = 10 male) aged 38–59 years under clinical follow-up. The patients were classified into two groups: (1) TAO former smokers (n = 11) and (2) TAO active smokers (n = 9); the control group included normal volunteer non-smokers (n = 10) and active smokers without peripheral artery disease (n = 10). Patient plasma samples were used to analyze MMP-2 and MMP-9 levels using zymography, and TIMP-1 and TIMP-2 concentrations were determined by enzyme-linked immunosorbent assays. The analysis of MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios (which were used as indices of net MMP-2 and MMP-9 activity, respectively) showed significantly higher MMP-9/TIMP-1 ratios in TAO patients (p < 0.05). We found no significant differences in MMP-2/TIMP-2 ratios (p > 0.05). We found higher MMP-9 levels and decreased levels of TIMP-1 in the TAO groups (active smokers and former smokers), especially in active smokers compared with the other groups (all p < 0.05). MMP-2 and TIMP-2 were not significantly different in patients with TAO as compared to the control group (p > 0.05). In conclusion, our results showed increased MMP-9 and reduced TIMP-1 activity in TAO patients, especially in active smokers compared with non-TAO patients. These data suggest that smoke compounds could activate MMP-9 production or inhibit TIMP-1 activity.Keywords
This publication has 32 references indexed in Scilit:
- Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodelingMatrix Biology, 2010
- Circulating Matrix Metalloproteinase-9 Is Associated with Cardiovascular Risk Factors in a Middle-Aged Normal PopulationPLOS ONE, 2008
- A role for matrix metalloproteinase-9 in the hemodynamic changes following acute pulmonary embolismInternational Journal of Cardiology, 2007
- Diagnostic Criteria and Treatment of Buerger’s Disease: A ReviewThe International Journal of Lower Extremity Wounds, 2006
- Thromboangiitis obliterans (Buergerʼs disease)Current Opinion in Rheumatology, 2006
- Dual Role of Matrix Metalloproteinases (Matrixins) in Intimal Thickening and Atherosclerotic Plaque RupturePhysiological Reviews, 2005
- Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart studyEuropean Heart Journal, 2004
- Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9)Critical Reviews in Biochemistry and Molecular Biology, 2002
- Angiotensin II induces TIMP-1 production in rat heart endothelial cellsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 1996
- Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.Journal of Clinical Investigation, 1994